Stimulus-Informed Generalized Canonical Correlation Analysis of Stimulus-Following Brain Responses

In brain-computer interface or neuroscience applications, generalized canonical correlation analysis (GCCA) is often used to extract correlated signal components in the neural activity of different subjects attending to the same stimulus. This allows quantifying the so-called inter-subject correlation or boosting the signal-to-noise ratio of the stimulus-following brain responses with respect to other (non-)neural activity. GCCA is, however, stimulus-unaware: it does not take the stimulus information into account and does therefore not cope well with lower amounts of data or smaller groups of subjects. We propose a novel stimulus-informed GCCA algorithm based on the MAXVAR-GCCA framework. We show the superiority of the proposed stimulus-informed GCCA method based on the inter-subject correlation between electroencephalography responses of a group of subjects listening to the same speech stimulus, especially for lower amounts of data or smaller groups of subjects

An Interpretable Performance Metric for Auditory Attention Decoding Algorithms in a Context of Neuro-Steered Gain Control

In a multi-speaker scenario, a hearing aid lacks information on which speaker the user intends to attend, and therefore it often mistakenly treats the latter as noise while enhancing an interfering speaker. Recently, it has been shown that it is possible to decode the attended speaker from the brain activity, e.g., recorded by electroencephalography sensors. While numerous of these auditory attention decoding (AAD) algorithms appeared in the literature, their performance is generally evaluated in a non-uniform manner. Furthermore, AAD algorithms typically introduce a trade-off between the AAD accuracy and the time needed to make an AAD decision, which hampers an objective benchmarking as it remains unclear which point in each algorithm's trade-off space is the optimal one in a context of neuro-steered gain control. To this end, we present an interpretable performance metric to evaluate AAD algorithms, based on an adaptive gain control system, steered by AAD decisions. Such a system can be modeled as a Markov chain, from which the minimal expected switch duration (MESD) can be calculated and interpreted as the expected time required to switch the operation of the hearing aid after an attention switch of the user, thereby resolving the trade-off between AAD accuracy and decision time. Furthermore, we show that the MESD calculation provides an automatic and theoretically founded procedure to optimize the number of gain levels and decision time in an AAD-based adaptive gain control system.status: publishe

A New Metric to Evaluate Auditory Attention Detection Performance Based on a Markov Chain

status: publishe

Tensor-based ECG Signal Processing Applied to Atrial Fibrillation Detection

status: publishe

Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia

<p><b>Aims:</b> Acute lymphoblastic leukemia (ALL) is an aggressive form of leukemia with a poor prognosis in adult patients. The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL. However, it is unknown whether the addition of rituximab is cost-effective. The objective was to determine the economic impact of rituximab in addition to standard of care (SOC) chemotherapy vs SOC alone in newly-diagnosed Philadelphia chromosome-negative, CD20-positive, B-cell precursor ALL.</p> <p><b>Methods:</b> A decision analytic model was constructed, based upon the Canadian healthcare system. It included the following health states over a lifetime horizon (max ≈60 years): event-free survival (EFS), relapsed/resistant disease, cure, and death. SOC was either hyper-CVAD or the Dana Farber Cancer Institute (DFCI) ALL consortium. EFS, overall survival, and serious adverse event (SAE) rates were derived from a large randomized controlled trial. Costs of the model included: first-line treatment and administration, disease management, second-line and third-line treatment and administration, palliative care, and SAE-related treatments. Inputs were sourced from provincial and national public data, the literature, and cancer agency input.</p> <p><b>Results:</b> Quality-adjusted life-years (QALYs) increased by 2.20 QALYs with rituximab in addition to SOC. The resulting mean Incremental Cost-Effectiveness Ratio (ICER) was C$21,828/QALY. At a willingness-to-pay threshold of C$100,000/QALY, the probability of being cost-effective was 98%. Decision outcomes were robust to the probabilistic and deterministic sensitivity analyses, including the SOC backbone as either hyper-CVAD or DFCI.</p> <p><b>Limitations:</b> The results of this analysis are limited by generalizability of the chemotherapy backbone to Canadian practice.</p> <p><b>Conclusions:</b> For adults with ALL, rituximab in addition to SOC was found to be a cost-effective intervention, compared to SOC alone. The addition of rituximab is associated with increased life years and increased QALYs at a reasonable incremental cost.</p